Table 2.
Cohort 2: demographic data, clinical characteristics and CSF levels of biomarkers
| Sample characteristics | Controls (n = 292) | SCD (n = 171) | MCI (n = 213) |
|---|---|---|---|
| Gender, F/M | 176/116 | 94/77 | 94/119∗∗∗ |
| Age, y | 73 (5) | 70 (6)∗∗∗ | 71 (6)∗∗∗ |
| MMSE | 29.1 (0.9) | 28.4 (1.4)∗∗∗ | 27.0 (1.9)∗∗∗ |
| APOE 1 or 2 ε4 alleles | 29% | 38%∗ | 49%∗∗∗ |
| Qalb | 5.9 (2.2) | 6.0 (2.4) | 6.5 (4.0) |
| Composite SUVRa | 1.3 (0.3) | 1.4 (0.4)∗∗ | 1.7 (0.5)∗∗∗ |
| BMI | 26.5 (4.3) | 25.1 (3.6) | 25.4 (4.2) |
| Homocysteine, μmol/L | 13.5 ± 4.1 | 12.6 ± 3.9 | 13.5 ± 4.1 |
| Diabetes, yes/no | 26/266 | 17/152 | 20/187 |
| Hyperlipidemia, yes/no | 124/168 | 22/147 | 19/188 |
| Aβ42, pg/mL | 561.9 (199.3) | 589.6 (254.6) | 470.5 (233.0)∗∗∗ |
| Aβ40, pg/mL | 4766 (1753) | 4925 (1751) | 4760 (1873) |
Data are shown as mean (standard deviation) unless otherwise specified. Demographic factors and clinical characteristics were compared using 1-way analysis of variance and chi-square tests. Qalb was analyzed with univariate general linear models controlling for age and gender, compared with controls ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
Key: Aβ, amyloid β; BMI, body mass index; F, female; M, male; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; Qalb, cerebrospinal fluid/plasma albumin ratio; SCD, subjective cognitive decline; SUVR, standardized uptake value ratio.
Normalized for the cerebellar cortex; amyloid positron emission tomography data were available from 342 subjects (129 cognitively normal elderly, 102 SCD patients, and 111 MCI patients).